Vimarsana
Biggest News Aggregation in the World

Timothya Springer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Timothya Springer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Timothya Springer Today - Breaking & Trending Today

HC Wainwright Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Vimarsana News

HC Wainwright Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)

HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $54.00 target price on the stock. A number of other research firms have also issued reports on RNAC. Needham & Company LLC reaffirmed a buy rating and […]

Cartesian Therapeutics' (RNAC) Buy Rating Reaffirmed at HC Wainwright - Vimarsana News

Cartesian Therapeutics' (RNAC) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. They currently have a $54.00 price target on the stock. Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a buy rating and set […]

Source: wkrb13.com
Cartesian Therapeutics' (RNAC) Buy Rating Reiterated at HC Wainwright - Vimarsana News

Cartesian Therapeutics' (RNAC) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $54.00 price objective on the stock. Several other analysts also recently weighed in on the company. Needham & Company LLC restated a buy […]

Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from HC Wainwright - Vimarsana News

Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $54.00 price objective on the stock. Other equities research analysts also recently issued reports about the stock. SVB Leerink assumed coverage on shares of Cartesian Therapeutics […]

Q2 2024 Earnings Estimate for Cartesian Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:RNAC) - Vimarsana News

Q2 2024 Earnings Estimate for Cartesian Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:RNAC)

Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) – Stock analysts at Leerink Partnrs boosted their Q2 2024 earnings estimates for Cartesian Therapeutics in a research note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($0.95) per share for the quarter, up from their prior […]

Source: wkrb13.com